Iovance Biotherapeutics, Inc. (IOVA)
NASDAQ: IOVA · Real-Time Price · USD
3.310
-0.070 (-2.07%)
At close: Apr 29, 2026, 4:00 PM EDT
3.320
+0.010 (0.30%)
After-hours: Apr 29, 2026, 4:54 PM EDT
Iovance Biotherapeutics Employees
Iovance Biotherapeutics had 975 employees as of December 31, 2025. The number of employees increased by 137 or 16.35% compared to the previous year.
Employees
975
Change (1Y)
137
Growth (1Y)
16.35%
Revenue / Employee
$270,258
Profits / Employee
-$401,003
Market Cap
1.36B
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Dec 31, 2025 | 975 | 137 | 16.35% |
| Dec 31, 2024 | 838 | 281 | 50.45% |
| Dec 31, 2023 | 557 | 54 | 10.74% |
| Dec 31, 2022 | 503 | 184 | 57.68% |
| Dec 31, 2021 | 319 | 78 | 32.37% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| Agios Pharmaceuticals | 540 |
| Immunocore Holdings | 524 |
| Ardelyx | 489 |
| Wave Life Sciences | 317 |
| Biohaven | 274 |
| Viridian Therapeutics | 252 |
| Precigen | 160 |
| Maze Therapeutics | 141 |
IOVA News
- 2 days ago - Iovance Biotherapeutics to Report First Quarter 2026 Financial Results and Corporate Updates on Thursday, May 7, 2026 - GlobeNewsWire
- 11 days ago - Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4) - GlobeNewsWire
- 7 weeks ago - Iovance Biotherapeutics Transcript: Barclays 28th Annual Global Healthcare Conference - Transcripts
- 7 weeks ago - What's Going On With Iovance Biotherapeutics Stock On Friday? - Benzinga
- 2 months ago - Iovance Biotherapeutics Transcript: TD Cowen 46th Annual Health Care Conference - Transcripts
- 2 months ago - Iovance Biotherapeutics to Present at Upcoming Conferences - GlobeNewsWire
- 2 months ago - Iovance Biotherapeutics Explodes Over 20% — Early Trial Data Sparks Investor Frenzy - Benzinga
- 2 months ago - Iovance Biotherapeutics Earnings Call Transcript: Q4 2025 - Transcripts